Frazer Therapeutics Successfully Secures 50 Billion Won in Investment
Frazer Therapeutics, a domestic company developing new drugs based on Targeted Protein Degradation (TPD) technology, has successfully closed a 50 billion won pre-IPO funding round.
This investment is significant as it demonstrates market recognition of the potential of the company's proprietary drug development technology. With the funds secured, Frazer Therapeutics plans to accelerate the research, development, and clinical trials of its current drug candidates.
Targeted protein degradation technology is a next-generation drug development method that eliminates disease-causing proteins that were previously difficult to address with conventional treatments, garnering significant attention from the global pharmaceutical and biotech industry. Frazer Therapeutics continues to grow based on its unique technological capabilities in this field.
The company intends to use the capital raised through this investment to strengthen its global competitiveness and accelerate preparations for an initial public offering. The industry is closely watching to see what achievements this company will reach in the future.